Loading...
•
Sep 30
Savara Q3 2025 Earnings Report
Savara reported a net loss of $29.6 million in Q3 2025 as it continued advancing its lead program, MOLBREEVI, toward regulatory milestones.
Key Takeaways
Savara posted a larger net loss in Q3 2025 compared to the previous year due to increased R&D and G&A expenses, as the company progresses its MOLBREEVI development and prepares for commercialization.
Net loss widened to $29.6 million from $24.2 million in Q3 2024
EPS came in at -$0.14 per share
Cash and short-term investments totaled $124.4 million at quarter-end
Significant investments made to support MOLBREEVI resubmission and commercial readiness
Savara
Savara
Forward Guidance
Savara remains on track to resubmit the BLA for MOLBREEVI in December 2025 and expects MAA submissions in early 2026, while recent financings have extended its cash runway to support commercialization.
Positive Outlook
- On track to resubmit MOLBREEVI BLA in December 2025
- Expecting MAA submissions in EU and UK in Q1 2026
- Recent equity raise added $140M to the balance sheet
- Presented supportive IMPALA-2 efficacy data
- Announced $75M royalty funding agreement for MOLBREEVI
Challenges Ahead
- No approved therapy yet for autoimmune PAP
- Still in pre-commercialization stage
- Net loss increased year-over-year
- Higher G&A costs impacting profitability
- Pending regulatory approvals introduce uncertainty